32 Biosciences, a gastrointestinal-focused biotechnology company, announced it will launch a $40 million Series A financing during the 2026 J.P. Morgan Healthcare Conference in San Francisco, scheduled for January 12–15, 2026.
The company said proceeds are intended to advance its lead program, CS-0003, a first-in-class Mucosal-Immune Modulator designed to protect and buffer the gastrointestinal tract by coating the mucosal barrier, suppressing bacterial virulence, and modulating the mucosal-immune system. 32 Biosciences’ initial target indication is the prevention of gastrointestinal surgical site infections, with potential future expansion into inflammatory bowel disease and prevention of colon cancer recurrence.
In parallel, 32 Biosciences is developing GB, a metabolomics-based GI discovery platform intended to quantify signatures of gut mucosal function and host–microbe interactions to support therapeutic discovery and development, and potentially enable future clinical decision support. The company said it plans to use the conference to meet with prospective investors and strategic partners to discuss the financing and planned use of proceeds, including moving CS-0003 into the clinic and progressing GB partnerships and validation.
KEY QUOTE:
“Launching our Series A at JPM is a key step as we advance CS-0003 into the clinic and build our GB discovery platform. We’re restoring and protecting the gut mucosal-immune system—an overlooked but central driver of surgical outcomes and chronic disease—with the goal of meaningfully improving outcomes for patients facing serious GI disease.”
Peter Farmakis, Chairman and Chief Executive Officer, 32 Biosciences
